Dehydroxymethylepoxyquinomicin(DHMEQ), a novel NF-kappaB inhibitor, inhibits allergic inflammation and airway remodeling in murine models of asthma
| Project/Area Number |
21659206
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Respiratory organ internal medicine
|
|---|
| Research Institution | Hokkaido University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TODO Satoru 北海道大学, 大学院・医学研究科, 特任教授 (60136463)
NASUHARA Yasuyuki 北海道大学, 北海道大学病院, 准教授 (30322811)
KONNO Satoshi 北海道大学, 大学院・医学研究科, 講師 (20399835)
|
|---|
| Project Period (FY) |
2009 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥3,250,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥150,000)
Fiscal Year 2011: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2010: ¥900,000 (Direct Cost: ¥900,000)
Fiscal Year 2009: ¥1,700,000 (Direct Cost: ¥1,700,000)
|
|---|
| Keywords | DHMEQ / NF-kB / 気管支喘息 / 難治性喘息 / 創薬 |
|---|
| Research Abstract |
DHMEQ significantly reduced eosinophilic airway inflammation and levels of Th2 cytokines in bronchoalveolar lavage fluid in murine asthma model. It also inhibited parameters of airway remodeling including mucus production, peribronchial fibrosis and the expression ofα-smooth muscle actin. These results indicate that DHMEQ inhibits allergic airway inflammation and airway remodeling in murine models of asthma. DHMEQ may have therapeutic potential in the treatment of asthma.
|
Report
(4 results)
Research Products
(10 results)
